Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.40+0.10 (+0.55%)
Close on Nov 18, 2026Market cap $1.33BP/E 9.3Yield –
Innoviva operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Innoviva's operating income for the twelve months ending Sep 30, 2026 was $170.15M, up 1.3% year over year. For fiscal 2025 it was $163.75M, down 1.9% from the year before. The highest annual figure on record is $375.10M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $163.75M | -1.9% |
| FY2024 | Dec 31, 2024 | $166.87M | +46.5% |
| FY2023 | Dec 31, 2023 | $113.89M | -69.6% |
| FY2021 | Dec 31, 2021 | $375.10M | +16.8% |
| FY2020 | Dec 31, 2020 | $321.12M | +30.3% |
| FY2019 | Dec 31, 2019 | $246.36M | +3.4% |
| FY2018 | Dec 31, 2018 | $238.25M | +29.8% |
| FY2017 | Dec 31, 2017 | $183.60M | +68.5% |
| FY2016 | Dec 31, 2016 | $108.99M | +245.1% |
| FY2015 | Dec 31, 2015 | $31.58M | – |
| FY2014 | Dec 31, 2014 | -$33.93M | – |
| FY2013 | Dec 31, 2013 | -$28.80M | – |
| FY2012 | Dec 31, 2012 | -$25.15M | – |
| FY2011 | Dec 31, 2011 | -$109.74M | – |
| FY2010 | Dec 31, 2010 | -$78.32M | – |
| FY2009 | Dec 31, 2009 | -$81.36M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $42.15M | +21.9% |
| Q2 FY2026 | Jun 30, 2026 | $50.86M | +4.3% |
| Q1 FY2026 | Mar 31, 2026 | $38.15M | -7.9% |
| Q4 FY2025 | Dec 31, 2025 | $38.99M | -9.6% |
| Q3 FY2025 | Sep 30, 2025 | $34.58M | -20.0% |
| Q2 FY2025 | Jun 30, 2025 | $48.75M | -10.9% |
| Q1 FY2025 | Mar 31, 2025 | $41.43M | +60.5% |
| Q4 FY2024 | Dec 31, 2024 | $43.14M | -47.7% |
| Q3 FY2024 | Sep 30, 2024 | $43.24M | -44.4% |
| Q2 FY2024 | Jun 30, 2024 | $54.69M | -47.7% |
| Q1 FY2024 | Mar 31, 2024 | $25.81M | -72.7% |
| Q2 FY2022 | Jun 30, 2022 | $82.55M | -14.5% |
| Q1 FY2022 | Mar 31, 2022 | $77.73M | -2.2% |
| Q4 FY2021 | Dec 31, 2021 | $104.53M | +23.3% |
| Q3 FY2021 | Sep 30, 2021 | $94.55M | +12.0% |
| Q2 FY2021 | Jun 30, 2021 | $96.54M | +27.4% |
| Q1 FY2021 | Mar 31, 2021 | $79.48M | +4.4% |
| Q4 FY2020 | Dec 31, 2020 | $84.79M | +15.1% |
| Q3 FY2020 | Sep 30, 2020 | $84.43M | +38.9% |
| Q2 FY2020 | Jun 30, 2020 | $75.79M | +26.8% |
| Q1 FY2020 | Mar 31, 2020 | $76.12M | +45.9% |
| Q4 FY2019 | Dec 31, 2019 | $73.64M | -4.6% |
| Q3 FY2019 | Sep 30, 2019 | $60.79M | +5.4% |
| Q2 FY2019 | Jun 30, 2019 | $59.76M | -4.7% |
| Q1 FY2019 | Mar 31, 2019 | $52.17M | +28.2% |
| Q4 FY2018 | Dec 31, 2018 | $77.22M | +16.3% |
| Q3 FY2018 | Sep 30, 2018 | $57.66M | +44.1% |
| Q2 FY2018 | Jun 30, 2018 | $62.68M | +31.0% |
| Q1 FY2018 | Mar 31, 2018 | $40.70M | +38.7% |
| Q4 FY2017 | Dec 31, 2017 | $66.41M | +76.3% |
| Q3 FY2017 | Sep 30, 2017 | $40.02M | – |
| Q2 FY2017 | Jun 30, 2017 | $47.83M | – |
| Q1 FY2017 | Mar 31, 2017 | $29.34M | – |
| Q4 FY2016 | Dec 31, 2016 | $37.66M | – |
See a number that looks wrong?